Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?
Bever
C T
CT
Rosenberg
G A
GA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000201:enzymology* / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism
D000276:Adjuvants, Immunologic; D019714:Tissue Inhibitor of Metalloproteinases; D016899:Interferon-beta; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9